3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Lymphoma
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Prostatic Neoplasms
11
Lymphoma, Large B-Cell, Diffuse
9
Lymphoma, Follicular
8
Leukemia
8
Lymphoma, Non-Hodgkin
7
Burkitt Lymphoma
5
Hodgkin Disease
4
Neoplasm Metastasis
3
Lymphoma, Large-Cell, Immunoblastic
3
Leukemia, Biphenotypic, Acute
3
Dendritic Cell Sarcoma, Interdigitating
3
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Neoplasms
2
Multiple Myeloma
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Urogenital Neoplasms
1
Thymoma
1
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Neurotoxicity Syndromes
1
Neoplasms, Plasma Cell
1
Myasthenia Gravis
1
Metastatic Castration-resistant Prostate Cancer
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, B-Cell, Marginal Zone
1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
1
Interventions
enzalutamide
2
ostarine
1
exemestane
1
abiraterone
1
Prednisolone
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Bulbo-Spinal Atrophy, X-Linked
×
Prednisolone
×
Clear all
NCT06764485
2026-05-06
rechARge
Celgene
Phase 3
Recruiting
960 enrolled